AXA/2026/1Q activity indicators press release: Difference between revisions

Content deleted Content added
PlumBot: publish from draft
PlumBot: publish from draft
 
Line 18:
== 1Q26 highlights ==
 
* Gross written premiums & other revenues (footnote: insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities).) '''+6%''' vs. 1Q25 to '''EUR 38.0bn''' <sup>p. 1</sup>
* Gross written premiums & other revenues '''+6%''' vs. 1Q25 to '''EUR 38.0bn''' <sup>p. 1</sup>
** Property & Casualty premiums '''+4%''' to '''EUR 21.5bn''' <sup>p. 1</sup>
*** Retail premiums '''+7%''' (+4% from price effect, +3% from volumes) <sup>p. 1</sup>
Line 25:
*** Life premiums '''+8%''' <sup>p. 1</sup>
*** Health premiums '''+8%''' <sup>p. 1</sup>
* Life & Health NB CSM (footnote: a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided.) '''+4%''' <sup>p. 1</sup>
* Life & Health NB CSM '''+4%''' <sup>p. 1</sup>
* Net flows (footnote: Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities.) '''+EUR 2.7bn''' <sup>p. 1</sup>
* Solvency II ratio (footnote: estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock. It includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of Euro 2.32 per share to be paid in 2026 for FY25 and annual share buyback of Euro 1.25 billion announced on February 26, 2026. Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stockbased compensation. Dividend s and share buybacks are proposed by the Board, at its discretion based on a variety of factors described in AXA's 202 5 Universal Registration Document and then submitted to AXA's shareholders for approval. This estimate should not be considered in any way to be an indication of the actual dividend and share buyback amounts, if any, for the 2026 financial year. For further information on AXA's internal model and Solvency II disclosures, please refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com).) '''211%''' as of March 31, 2026 <sup>p. 1</sup>
** Solvency II ratio was '''211%''' as of March 31, 2026, downDown '''-4 points''' vs. January 1, 2026 (post-grandfathering period), reflecting resilience in a volatile environment <sup>p. 1</sup>
 
== Outlook 3 ==
Line 33 ⟶ 34:
* AXA is on track to achieve underlying earnings per share growth for 2026 at the upper end of the '''6-8%''' plan target range <sup>p. 1</sup>
* AXA will present its new strategic plan for 2027-2029 on September 15, 2026 <sup>p. 1</sup>
* Forward-looking statement: Expected underlying earnings per share ('UEPS') growth for 2026 is guidance for the last year of the current strategic plan and is subject to cautionary statements regarding forward-looking statements <sup>p. 7</sup>
* The Solvency II ratio is estimated using AXA's internal model calibrated based on an adverse 1/200 years shock <sup>p. 7</sup>
* The Solvency II ratio estimate includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026 <sup>p. 7</sup>
* The theoretical dividend amount is based on the full-year dividend of '''EUR 2.32 per share''' to be paid in 2026 for FY25 <sup>p. 7</sup>
* The theoretical share buyback amount is based on an annual share buyback of '''EUR 1.25bn''' announced on February 26, 2026 <sup>p. 7</sup>
* Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation <sup>p. 7</sup>
* Dividends and share buybacks are proposed by the Board, at its discretion, and submitted to shareholders for approval <sup>p. 7</sup>
* The Solvency II estimate should not be considered an indication of actual dividend and share buyback amounts for the 2026 financial year <sup>p. 7</sup>
* For more information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on www.axa.com <sup>p. 7</sup>
* The underlying earnings per share growth target assumes no significant deterioration in current operating, pricing, and market conditions <sup>p. 7</sup>
* The underlying earnings per share growth target is based on a Natural Catastrophe load of approximately '''4.5 points''', defined as normalized natural catastrophe losses expected in a year expressed as a percentage of gross earned premiums <sup>p. 7</sup>
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>
 
<blockquote>"AXA delivered a strong start to the year, with topline growth across all business lines, fully aligned with our organic growth strategy. This performance underscores the continued robust expansion of our P&C businesses in both Retail and Commercial, with growth well balanced between pricing and volumes, while Life & Health revenues reflect the continuation of last year's strong momentum." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
 
<blockquote>"In the context of a volatile macro environment, we operate from a position of strength, supported by a robust balance sheet, a Solvency II ratio of 211% and a high-quality investment portfolio. This gives us strong resilience and flexibility. We remain confident in our ability to deliver underlying earnings per share growth for 2026 at the top end of our target range and to sustain growth beyond the current plan." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
 
<blockquote>"I would like to express my gratitude to our colleagues, agents, and partners for their dedication, as well as to our clients for their continued trust in AXA." <small>(Alban de Mailly Nesle, Chief Financial Officer of AXA <sup>p. 1</sup>)</small></blockquote>
 
Line 55 ⟶ 41:
 
* The press release was issued in Paris on May 5, 2026, at 5:45pm CET <sup>p. 1</sup>
* The document covers 1Q26 Activity indicators, showhighlighting sustained revenue momentum <sup>p. 1</sup>
* All footnotes for this press release are on page 7 <sup>p. 1</sup>
 
Line 62 ⟶ 48:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26 Keykey Highlightshighlights: Grossgross Writtenwritten Premiumspremiums and Otherother Revenuesrevenues. <sup>p. 2</sup>
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 97 ⟶ 83:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26 Keykey Highlightshighlights: Solvency II Ratioratio. <sup>p. 2</sup>
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | FY25
Line 117 ⟶ 103:
** Property & Casualty '''+4%''' <sup>p. 2</sup>
*** Personal lines '''+7%''' (driven by higher volumes and favorable price effect) <sup>p. 2</sup>
*** Commercial lines (footnote: P&C Commercial lines excluding AXA XL Reinsurance.) '''+3%''' (from higher volumes, notably at AXA XL Insurance, and favorable price effect mainly in SME & Mid-market business in Europe and France) <sup>p. 2</sup>
*** AXA XL Reinsurance '''-7%''' (reflecting discipline in softening market conditions) <sup>p. 2</sup>
** Life & Health '''+8%''' <sup>p. 2</sup>
*** Life premiums '''+8%''' (driven by strong sales in Unit-Linked (+16%), and G/A (footnote: General account.) (+9%) across all geographies, and Protection (+4%) from strong sales in Protection with Savings in Hong Kong and Japan) <sup>p. 2</sup>
*** Health premiums '''+8%''' (driven by favorable price effects across all geographies) <sup>p. 2</sup>
* Solvency II ratio was '''211%''' as of March 31, 2026 <sup>p. 2</sup>
** On January 1, 2026, the Solvency II ratio was '''215%''' following the end of the grandfathering period (footnote: Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, at which point they ceased to qualify as capital under Solvency II, as disclosed in AXA's respective press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings, each published on www.axa.com.) (-10 points vs. December 31, 2025) <sup>p. 2</sup>
* The* Solvency II ratio was down '''-4 points''' vs. January 1, 2026, due to: <sup>p. 2</sup>
*** StrongReflecting a strong operating return ('''+7 points'''), less accrued dividend and annual share buyback for 1Q26 ('''-6 points''') <sup>p. 2</sup>
*** LessMore accruedthan dividendoffset andby annualunfavorable sharefinancial buybackmarket for 1Q26movements ('''-64 points'''), notably from higher inflation expectations and elevated equity and interest rate volatility <sup>p. 2</sup>
** Unfavorable financial market movements ('''-4 points'''), notably from higher inflation expectations and elevated equity and interest rate volatility <sup>p. 2</sup>
 
== Property & Casualty ==
Line 133 ⟶ 118:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Property & Casualty: Grossgross Writtenwritten Premiumspremiums and Otherother Revenuesrevenues. <sup>p. 3</sup>
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 166 ⟶ 151:
</div>
 
* Gross written premiums & other revenues for Property P& CasualtyC were '''+4%''' to '''EUR 21.5bn''' <sup>p. 3</sup>
* Personal lines grew by '''+7%''' to '''EUR 7.0bn''', driven by: <sup>p. 3</sup>
** Europe ('''+7%''') (from favorable price effects across geographies (except UK & Ireland), and higher volumes) <sup>p. 3</sup>
** France ('''+8%''') (with strong volume growth from direct business and proprietary agent networks, combined with favorable price effect) <sup>p. 3</sup>
** Asia, Africa & EME LATAM ('''+7%'''), (mainly driven by higher average premiums in Türkiye and higher volumes in Mexico) <sup>p. 3</sup>
* Commercial lines grew by '''+3%''' to '''EUR 13.2bn''', mainly from: <sup>p. 3</sup>
** AXA XL Insurance ('''+2%''') (from growth in Property and Specialty where margins remain attractive, partly offset by lower volumes in Casualty; pricing overall stable vs. 1Q25) <sup>p. 3</sup>
** PricingFrance for'''+6%''' AXA(from XLboth Insurancefavorable remainsprice stableeffect overalland versushigher 1Q25volumes) <sup>p. 3</sup>
** FranceAsia, Africa & EME-LATAM ('''+610%''') from(mainly bothdriven favorableby pricehigher effectaverage andpremiums higherin volumesTürkiye) <sup>p. 3</sup>
** Asia,AXA AfricaXL &Reinsurance EME-LATAMdecreased by ('''+107%'''), mainlyto driven'''EUR by higher average premiums in Türkiye1.2bn''' <sup>p. 3</sup>
** AXA XL Reinsurance decreased '''-7%''' to '''EUR 1.2bn''', reflectingReflects lower volumes, dueconsistent towith focus on maintaining profitability in a softer market environment <sup>p. 3</sup>
** AXA XL Reinsurance pricing wasPricing down '''-4%''' <sup>p. 3</sup>
* Group natural catastrophe experience in 1Q26 was slightly below the prorated annual budget <sup>p. 3</sup>
* The annual natural catastrophe (footnote: Natural catastrophe charges include natural catastrophe losses regardless of event size.) budget of ca. '''4.5 points''' of combined ratio (footnote: a nonGAAP financial measure, or alternative performance measure ('APM'). Please see the paragraph 'Important legal information and cautionary statements concerning forward-looking statements and the use of nonGAAP financial measures' i n this press release for important information about APMs used by AXA.) is maintained <sup>p. 3</sup>
* The annual natural catastrophe budget of approximately '''4.5 points''' of combined ratio is maintained <sup>p. 3</sup>
 
== Life & Health ==
Line 185 ⟶ 170:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Life & Health: Grossgross Writtenwritten Premiumspremiums, andPVEP, OtherNB RevenuesCSM, NBV, and New Businessnet Metricsflows. <sup>p. 4</sup>
! style="text-align:left" | Key figures (EUR billion)
! style="text-align:right; width:6em" | 1Q25
Line 242 ⟶ 227:
</div>
 
* For comparability, 1Q25 PVEP, NB CSM, NBV, and NBV margin have been updated based on FY25 financial and actuarial assumptions for comparability <sup>p. 4</sup>
* All year-on-year changes are on a comparable basis versus the updated 1Q25 figures <sup>p. 4</sup>
* Gross written premiums & other revenues for Life & Health were '''+8%''' to '''EUR 16.5bn''' <sup>p. 4</sup>
* Life premiums increased by '''+8%''' to '''EUR 10.5bn''', driven by: <sup>p. 4</sup>
** Unit-Linked ('''+16%''') (from continuedcontinuation of positive sales momentum across geographies) <sup>p. 4</sup>
** G/A Savings ('''+9%'''), (mainly from successful commercial campaigns in Spain, strong single-premium sales in Japan, good performance of G/A capital-light products in Italy, and positive momentum in Individual Savings in Switzerland) <sup>p. 4</sup>
** Protection ('''+4%'''), (primarily from continued success of Protection with G/A savings in Hong -Kong and Protection with Unit-Linked in Japan, as well as Individual Protection with Savings in Switzerland) <sup>p. 4</sup>
* Health premiums increased by '''+8%''' to '''EUR 5.9bn''', (driven by favorable price effects across all geographies) <sup>p. 4</sup>
* '''Present value of expected premiumsPVEP ('PVEP')'''footnote: the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share.) '''+8%''' to '''EUR 13.8bn''' <sup>p. 54</sup>
* PVEP '''+8%''' to '''EUR 13.8bn''', driven by: <sup>p. 4</sup>
** Life ('''+10%'''), (reflecting strong sales across geographies in both Savings ('''+14%''') and Protection ('''+6%'''), partly offset by lower Group Life sales in Switzerland) <sup>p. 4</sup>
** Health ('''+4%'''), (mainly due to higher Group business volumes in France, partly offset by Japan) <sup>p. 4</sup>
* NB CSM (pre-tax) increased '''+4%''' to '''EUR 0.6bn''', driven by strong Savings and Protection sales across most geographies, partly offset by unfavorable mix (including lower Group Life sales in Switzerland and Health sales in Japan) <sup>p. 4</sup>
** Driven by strong Savings and Protection sales across most geographies <sup>p. 4</sup>
* NBV (post-tax) '''+1%''' to '''EUR 0.6bn''', as NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup>
** Partly offset by unfavorable mix, including lower Group Life sales in Switzerland and Health sales in Japan <sup>p. 4</sup>
* NBV margin decreased '''-0.3 points''' to '''4.4%''' <sup>p. 4</sup>
* NBV (post-tax) (footnote: the value of newly issued contracts during the current year. It consists of the sum of (i) the NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued contracts during the period, carried by Life entities, considering expected renewals, and (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests.) '''+1%''' to '''EUR 0.6bn''' <sup>p. 4</sup>
* Net flows were '''EUR +2.7bn''', compared to '''EUR +2.5bn''' in 1Q25, driven by: <sup>p. 4</sup>
* NBV (post-tax) '''+1%''' to '''EUR 0.6bn''', as* NB CSM growth was partly offset by lower sales and a less favorable mix in Joint Ventures in Thailand and China <sup>p. 4</sup>
* NBV margin (footnote: the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP.) decreased by '''0.3 point''' to '''4.4%''' <sup>p. 4</sup>
* Net flows were '''EUR +2.7bn''', compared(prior: to '''EUR +2.5bn''' in 1Q25, driven by:) <sup>p. 4</sup>
** Protection ('''EUR +1.8bn'''), mainly in Hong Kong and Switzerland in Individual Life, and in Japan in Protection with Unit-Linked product <sup>p. 4</sup>
** Unit-Linked ('''EUR +0.7bn'''), primarily in France <sup>p. 4</sup>
** G/A Savings ('''EUR -0.8bn'''), reflecting inflows in capital-light G/A savings ('''EUR +0.7bn'''), more than offset by outflows in traditional G/A Savings ('''EUR -1.5bn''') <sup>p. 4</sup>
** Health ('''EUR +1.0bn'''), mostly from Germany, France, and Japan <sup>p. 4</sup>
 
== Ratings ==
Line 266 ⟶ 254:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Insurer Financialfinancial Strengthstrength and CreditAXA's Ratingscredit ratings. <sup>p. 5</sup>
! style="text-align:left" | —
! style="text-align:right; width:9em" | —
Line 299 ⟶ 287:
 
== Glossary ==
* '''Capital-light G/A products''': encompass all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 5</sup>
* '''Contractual service margin ('CSM')''': a component of the carrying amount of anthe asset or liability for a group of insurance contracts, representing the unearned profit to be recognized as services are provided to policyholders <sup>p. 5</sup>
* '''Gross written premiums and other revenues''': insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities) <sup>p. 5</sup>
* '''New business contractual service margin ('NB CSM')''': a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided <sup>p. 5</sup>
* '''Other Revenues''': premiums and fees collected on activities other than insurance (i.e., banking, services, and asset management activities) <sup>p. 5</sup>
* '''New business contractual service marginvalue ('NB CSMNBV')''': athe componentvalue of newly issued contracts during the carryingcurrent amountyear. It consists of anthe assetsum orof liability(i) forthe NB CSM, (ii) the present value of the future profits of Short-Term Business newly issued insurance contracts during the period, representingcarried unearnedby profitLife toentities, beconsidering recognizedexpected asrenewals, insuranceand contract(iii) servicesthe present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) areminority providedinterests <sup>p. 5</sup>
* '''New business value margin ('NBV Margin')''': the ratio of (i) NBV representing the value of newly issued contracts during the current year to (ii) PVEP <sup>p. 5</sup>
** It'''Present isvalue theof sumexpected ofpremiums (i'PVEP')''': NBthe CSMnew business volume, (ii)equal to the present value ofat futurethe profitstime of Short-Termissue Businessof newlythe issuedtotal contractspremiums byexpected Lifeto entitiesbe (consideringreceived expectedover renewals),the andpolicy (iii)term. presentPVEP valueis ofdiscounted futureat profitsthe ofreference pureinterest investmentrate contractsand accountedPVEP for underis IFRSGroup 9share <sup>p. 5</sup>
* '''IIAM''': SolvencyAM IIBest
** Net of (iv) cost of reinsurance, (v) taxes, and (vi) minority interests <sup>p. 5</sup>
* '''AMF''': Autorité des marchésMarchés financiersFinanciers
* '''New business value margin ('NBV Margin')''': the ratio of (i) NBV to (ii) PVEP <sup>p. 5</sup>
* '''Present value of expected premiums ('PVEP')''': the new business volume, equal to the present value at the time of issue of total premiums expected to be received over the policy term <sup>p. 5</sup>
* PVEP is discounted at the reference interest rate and is Group share <sup>p. 5</sup>
* '''AMF''': Autorité des marchés financiers
* '''APM''': Alternative Performance Measure
* '''CLP''': Credit and Lifestyle Protection
Line 316 ⟶ 301:
* '''DJSI''': Dow Jones Sustainability Index
* '''DPF''': Discretionary Participation Features
* '''EME LATAM''': Emerging Markets Europe and Latin America
* '''EME''': Emerging Markets Europe
* '''ESMA''': European Securities and Markets Authority
Line 322 ⟶ 306:
* '''GWP''': Gross Written Premiums
* '''IFRS''': International Financial Reporting Standards
* '''II''': Solvency II
* '''LFL''': Like-for-Like
* '''NB CSM''': New Business Contractual Service Margin
Line 330 ⟶ 313:
* '''SFCR''': Solvency and Financial Condition Report
* '''SME''': Small and Medium-sized Enterprises
* '''SRI''': Socially Responsible InvestingInvestment
* '''UEPS''': Underlying Earnings Per Share
* '''UN''': United Nations
Line 336 ⟶ 319:
== Scope ==
 
* '''France''': includes insurance activities, banking activities, and holding <sup>p. 6</sup>
* '''Europe''': includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and LuxembourgLuxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holding), Italy (insurance activities), Prima (insurance activities), AXA Health International (insurance activities), and AXA Life Europe (insurance activities) <sup>p. 6</sup>
* '''AXA XL''': includes insurance and reinsurance activities and holding <sup>p. 6</sup>
* '''Asia, Africa & EME-LATAM''': <sup>p. 6</sup>
** '''Asia''': Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, Indonesia L&S (excludingexcl. the bancassurance entity), China P&C, South Korea, and Asia Holdings are (fully consolidated) <sup>p. 6</sup>
** '''Asia (equity method)''': China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S (the bancassurance entity) are consolidated under the equity method and (contribute only to NBV, PVEP, underlying earnings, and net income) <sup>p. 6</sup>
** '''Africa''': Egypt (insurance activities and holding), Morocco (insurance activities and holding), and Nigeria (insurance activities and holding) are (fully consolidated) <sup>p. 6</sup>
** '''EME-LATAM''': Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding), and Türkiye (insurance activities and holding) are (fully consolidated) <sup>p. 6</sup>
** '''EME-LATAM (equity method)''': Russia (Reso) (insurance activities) is consolidated under the equity method and (contributes only to net income) <sup>p. 6</sup>
** Also includes'''Other''': AXA Mediterranean Holdings <sup>p. 6</sup>
* '''Transversal & Other''': includes AXA Assistance, Credit and Lifestyle Protection (CLP), AXA Liabilities Managers, AXA SA (includingincl. the Group's internal reinsurance activity), and other Central Holdings <sup>p. 6</sup>
* '''AXA Investment Managers''': disposal to BNP Paribas completed on July 1, 2025 <sup>p. 6</sup>
 
Line 353 ⟶ 336:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ End of Periodperiod and Averageaverage Exchangeexchange Ratesrates. <sup>p. 6</sup>
! style="text-align:left" | —
! colspan="2" style="text-align:center" | End of Period Exchange rate
Line 392 ⟶ 375:
== Notes ==
 
* ChangesChange in gross written premiums & other revenues, new business value ('NBV'), present value of expected premiums ('PVEP'), and new business value margin ('NBV Margin') areis on a comparable basis (constant forex, scope, and methodology), unless otherwise indicated <sup>p. 7</sup>
* These and other terms are defined in the glossary section of this press release <sup>p. 7</sup>
* The Solvency II ratio is estimated primarily using AXA's internal model calibrated based on an adverse 1/200 years shock <sup>p. 7</sup>
* The estimateIt includes a theoretical amount for dividends and share buybacks accrued for the first three months of 2026, based on the full-year dividend of '''EUR 2.32''' per share''' to be paid in 2026 for FY25 and an annual share buyback of '''EUR 1.25bn''' announced on February 26, 2026 <sup>p. 7</sup>
* Annual share buybacks exclude anti-dilutive share buybacks related to certain disposals and in-force management transactions, as well as share buybacks to offset dilutive effects relating to employee share offerings and stock-based compensation <sup>p. 7</sup>
* Dividends and share buybacks are proposed by the Board, at its discretion, based on a variety of factors described in AXA's 2025 Universal Registration Document and then submitted to AXA's shareholders for approval <sup>p. 7</sup>
* This estimate should not be considered an indication of the actual dividend and share buyback amounts for the 2026 financial year <sup>p. 7</sup>
* For further information on AXA's internal model and Solvency II disclosures, refer to AXA Group's Solvency and Financial Condition Report (SFCR) as of December 31, 2024, available on AXA's website (www.axa.com) <sup>p. 7</sup>
* Expected underlying earnings per share ('UEPS') growth for 2026 is a forward-looking statement to provide one-off guidance forin the context of the last year of the Group's current strategic plan <sup>p. 7</sup>
* This guidancestatement is qualified by cautionary statements in this press release regarding forward-looking statements <sup>p. 7</sup>
* The guidance assumes no significant deterioration in current operating, pricing, and market conditions, and is based on a Natural Catastrophe load of approximately '''4.5 points''' <sup>p. 7</sup>
* Natural Catastrophe load is defined as normalized natural catastrophe losses expected in a year expressed as a percentage of gross earned premiums in the same year <sup>p. 7</sup>
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>
* 'Commercial lines' refers to P&C Commercial lines excluding AXA XL Reinsurance <sup>p. 7</sup>
* Price effect is calculated as a percentage of total gross written premiums of the prior year <sup>p. 7</sup>
* General account (G/A refers to General account) <sup>p. 7</sup>
* Capital instruments and subordinated debt subject to Solvency II transitional measures were grandfathered until January 1, 2026, afterat which point they ceased to qualify as capital under Solvency II <sup>p. 7</sup>
* This was disclosed in AXA's press releases on its 9M25 Activity Indicators and Full Year 2025 Earnings, published on www.axa.com <sup>p. 7</sup>
* Natural catastrophe charges include natural catastrophe losses regardless of event size <sup>p. 7</sup>
* Combined ratio is a non-GAAP financial measure, or alternative performance measure ('APM') <sup>p. 7</sup>
* Important information about APMs used by AXA can be found in the paragraph 'Important legal information and cautionary statements concerning forward-looking statements and the use of non-GAAP financial measures' in this press release <sup>p. 7</sup>
* Life & Health net flows, PVEP, NB CSM, NBV, and NBV margin include Health business predominantly written in Life entities <sup>p. 7</sup>
* Restricted Tier 1 is rated 'A' by Standard & Poor's and 'A3 (hyb)' by Moody's <sup>p. 7</sup>
* Tier 2 is rated 'A' by Standard & Poor's and 'A1A (hyb)' by Moody's <sup>p. 7</sup>
* AXA completed its acquisition of a majority stake in Prima in Italy on November 28, 2025 <sup>p. 7</sup>
* All comments and changes for activity indicators are on a comparable basis for activity indicators (constant forex, scope, and methodology) <sup>p. 7</sup>
* Actuarial and financial assumptions used for the calculation of NBV and PVEP are updated semi-annually at half year and full year <sup>p. 7</sup>
* Financial figures and information in this press release have not been audited and have not been subject to any limited review by AXA's statutory auditors <sup>p. 7</sup>
Line 422 ⟶ 402:
== About the AXA Group ==
 
* AXA Group is a worldwide leader in insurance with '''156,000 employees''' employees serving over '''92 million clients''' clients in '''52 countries''' countries <sup>p. 8</sup>.
* In 2025, AXA's revenues were '''EUR 115.5bn''' and underlying earnings were '''EUR 8.4bn''' <sup>p. 8</sup>.
* The AXA ordinary share is listed on compartment A of Euronext Paris under ticker symbol '''CS''' (ISN '''FR 0000120628'''; Bloomberg: '''CS FP'''; Reuters: '''AXAF.PA''') <sup>p. 8</sup>.
* AXA's American Depository Share is quoted on the OTC QX platform under ticker symbol '''AXAHY''' <sup>p. 8</sup>.
* AXA Group is included in main international SRI indexes, likeincluding Dow Jones Sustainability Index (DJSI) and FTSE4GOOD <sup>p. 8</sup>.
* AXA is a founding member of the UN Environment Programme's Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment <sup>p. 8</sup>.
* ThisPress press releasereleases and regulated information are available on the AXA Group website (axa.com) <sup>p. 8</sup>.
* Forward-looking statements in thisthe press release, including those regarding expected underlying earnings per share (UEPS) growth for 2026, are based on Management's current views and intentions and are subject to change <sup>p. 8</sup>.
* Undue reliance should not be placed on forward-looking statements due to known and unknown risks and uncertainties, many outside AXA's control, which could cause actual results to differ materially <sup>p. 8</sup>.
* Each forward-looking statement is valid only at the date of this press release <sup>p. 8</sup>.
* For a description of important factors, risks, and uncertainties, refer to Part 5 'Risk Factors and Risk Management' of AXA's 2025 Universal Registration Document <sup>p. 8</sup>.
* AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations <sup>p. 8</sup>.
* This press release refers to nonNon-GAAP financial measures (Alternative Performance Measures or APMs) are used by Management for analyzing operating trends, financial performance, and position, and may not be comparable to similarly labeled measures from other companies <sup>p. 8</sup>.
* These non-GAAP financial measures generally have no standardized meaning and may not be comparable to similarly labeled measures used by other companies <sup>p. 8</sup>.
* Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Group's consolidated financial statements prepared in accordance with IFRS <sup>p. 8</sup>.
* '"Underlying earnings'", UEPS, '"underlying return on equity'", '"combined ratio'", and '"debt gearing'" are APMs as defined inby ESMA's guidelines and the AMF's related position statement issued in 2015 <sup>p. 8</sup>.
* Reconciliations of APMs to financial statements are provided in the 2025 Universal Registration Document, Section 2.3.3 'Alternative Performance Measures' <sup>p. 8</sup>.
* MediaInvestor Relations contact: '''+33.1.40.75.4648.7442''', ziadinvestor.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulakrelations@axa.com <sup>p. 8</sup>.
* For more information on non-GAAP financial measures, see the Glossary in the 2025 Universal Registration Document <sup>p. 8</sup>.
* InvestorIndividual Shareholder Relations contact: '''+33.1.40.75.48.42, investor.relations@axa.com43''' <sup>p. 8</sup>.
* Individual ShareholderMedia Relations contact: '''+33.1.40.75.4846.74''', ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.43com <sup>p. 8</sup>.
* Media Relations contact: +33.1.40.75.46.74, ziad.gebran@axa.com, ahlem.girard@axa.com, sylwia.tulak@axa.com <sup>p. 8</sup>.
* Corporate Responsibility strategy information is available at axa.com/en/about-us/strategy-commitments <sup>p. 8</sup>.
* SRI ratings information is available at axa.com/en/investor/sri-ratings-ethical-indexes <sup>p. 8</sup>.
Line 448 ⟶ 424:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ GrossGWP Written& Premiumsother andrevenues Otherby Revenuesregion byand business Segmentline. <sup>p. 9</sup>
! style="text-align:left" | EUR million
! colspan="5" style="text-align:center" | GWP & Other Revenues
Line 544 ⟶ 520:
</div>
 
* Banking revenues amounted towere '''EUR 26m''' in 1Q26 and '''EUR 25m''' in 1Q25 <sup>p. 9</sup>.
* Portfolio of lifestyle and income protection (CLP) premiums reallocated from France to Transversal <sup>p. 9</sup>.:
*** CLP premiums were1Q25: '''EUR 198m''' in(of 1Q25which ('''EUR 68m''' in P&C, and '''EUR 130m''' in Life & Health) <sup>p. 9</sup>.
*** CLP premiums were1Q26: '''EUR 201m''' in(of 1Q26which ('''EUR 68m''' in P&C, and '''EUR 132m''' in Life & Health) <sup>p. 9</sup>.
* International protection and health premiums previously recorded in AXA France are now reported under the new carrier AXA Health International, which is part of Europe <sup>p. 9</sup>.
*** These premiums were1Q25: '''EUR 319m''' in(of 1Q25which ('''EUR 104m''' in Life, and '''EUR 215m''' in Health) <sup>p. 9</sup>.
*** These premiums were1Q26: '''EUR 336m''' in(of 1Q26which ('''EUR 103m''' in Life, and '''EUR 233m''' in Health) <sup>p. 9</sup>.
 
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ PropertyCommercial &and Casualtypersonal Gross Written Premiumslines by Segment and Lineregion. <sup>p. 10</sup>
! style="text-align:left" | EUR million
! colspan="2" style="text-align:center" | Commercial lines
Line 666 ⟶ 642:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ ExchangeCurrency Ratesexchange rates for FY25 and 1Q26. <sup>p. 10</sup>
! style="text-align:left" | —
! style="text-align:right; width:6em" | FY25 i
Line 699 ⟶ 675:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ P&C Priceprice Effecteffect by Countrycountry and Businessbusiness Lineline for 1Q26. <sup>p. 11</sup>
! style="text-align:left" | 1Q26 (in %)
! style="text-align:right; width:6em" | Commercial lines
Line 761 ⟶ 737:
|}
</div>
 
* No facts in this section.
 
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Life & Health Gross Written Premiumsbusiness by Segmentregion and Productproduct Typetype. <sup>p. 12</sup>
! style="text-align:left" | EUR million
! colspan="2" style="text-align:center" | Total i
Line 876 ⟶ 850:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q25 Updatedupdated Lifefigures &for Healthlife Figuresand byhealth Segmentbusiness. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! colspan="4" style="text-align:center" | Life
Line 970 ⟶ 944:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1H25 Updatedupdated Lifefigures &for Healthlife Figuresand byhealth Segmentbusiness. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! colspan="4" style="text-align:center" | Life
Line 1,064 ⟶ 1,038:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 9M25 Updatedupdated Lifefigures &for HealthPVEP, NewNB BusinessCSM, MetricsNBV, byand SegmentNBV margin. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! style="text-align:right; width:6em" | PVEP
Line 1,153 ⟶ 1,127:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q25 Updatedupdated figures for NB CSM to NBV Figures. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! style="text-align:centerright; width:6em" | Life
! style="text-align:centerright; width:6em" | Health i
! style="text-align:centerright; width:6em" | Total i
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | NB CSM (pre-tax)
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | Other NBV (pre-tax)
|-
! style="text-align:left" | —
! colspan="3" style="text-align:center" | Total NBV
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,192 ⟶ 1,157:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1H25 Updatedupdated figures for NB CSM to NBV Figures. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! style="text-align:centerright; width:6em" | Life
! style="text-align:centerright; width:6em" | Health i
! style="text-align:centerright; width:6em" | Total i
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | NB CSM (pre-tax)
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | Other NBV (pre-tax)
|-
! style="text-align:left" | —
! colspan="3" style="text-align:center" | Total NBV
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,231 ⟶ 1,187:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 9M25 Updatedupdated figures for NB CSM to NBV Figures. <sup>p. 13</sup>
! style="text-align:left" | EUR million
! style="text-align:centerright; width:6em" | Life
! style="text-align:centerright; width:6em" | Health i
! style="text-align:centerright; width:6em" | Total i
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | NB CSM (pre-tax)
|-
! style="text-align:left" |
! colspan="3" style="text-align:center" | Other NBV (pre-tax)
|-
! style="text-align:left" | —
! colspan="3" style="text-align:center" | Total NBV
|-
| style="text-align:left" | NB CSM (pre-tax)
Line 1,272 ⟶ 1,219:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ 1Q26 Lifenew &business Healthmetrics Newfor Businesslife Metricsand health by Segmentregion. <sup>p. 14</sup>
! style="text-align:left" | EUR million
! colspan="8" style="text-align:center" | Life New Business Metrics 1Q26
Line 1,438 ⟶ 1,385:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ NB CSM to NBV Figuresfor life and health. <sup>p. 14</sup>
! style="text-align:left" | EUR million
! style="text-align:right; width:6em" | Life
Line 1,466 ⟶ 1,413:
</div>
 
* Includes Health business predominantly written predominantly in Life entities is included <sup>p. 14</sup>.
* Changes are atpresented on a comparable basis (constant forex, scope, and methodology) <sup>p. 14</sup>.
 
=== Net flows by business line ===
Line 1,473 ⟶ 1,420:
<div style="overflow-x:auto">
{| class="wikitable" style="width:100%"
|+ Net Flowsflows by Lifebusiness &line Healthfor Business1Q25 Lineand 1Q26. <sup>p. 15</sup>
! style="text-align:left" | EUR billion
! style="text-align:right; width:6em" | 1Q25
Line 1,508 ⟶ 1,455:
</div>
 
* Includes Health business predominantly written predominantly in Life entities is included <sup>p. 15</sup>.
* Capital light G/A encompasses all products with no guarantees, with guarantees at maturity only, or with guarantees equal to or lower than 0% <sup>p. 15</sup>.
* Includes Investment contracts with no discretionary participation features ('DPF') are included <sup>p. 15</sup>.
* A share repurchase agreement for up to '''EUR 1.25bn''' was announced on February 27, 2026 <sup>p. 16</sup>.
* Next main investor events:
* Next main investor events include: HY26 Earnings Release (July 31, 2026), AXA Investor Day (September 15, 2026), AXA Investor roundtable on strategy for key markets (September 21, 2026), and 9M26 Activity Indicators (October 29, 2026) <sup>p. 16</sup>.
*** HY26 Earnings Release on July 31, 2026 <sup>p. 16</sup>.
*** AXA Investor Day on September 15, 2026 <sup>p. 16</sup>.
*** AXA Investor roundtable on the strategy for AXA key markets on September 21, 2026 <sup>p. 16</sup>.
*** 9M26 Activity Indicators on October 29, 2026 <sup>p. 16</sup>.